- Home
- TGB vs COLL Comparison
TGB vs COLL Comparison
Compare TGB & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGB | COLL |
|---|---|---|
| Founded | 1966 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | TGB | COLL |
|---|---|---|
| Price | $5.18 | $48.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.00 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 6.2M | 528.3K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | $428,559,326.00 | ★ $757,067,000.00 |
| Revenue This Year | $10.35 | $26.35 |
| Revenue Next Year | $61.39 | $3.67 |
| P/E Ratio | ★ N/A | $29.97 |
| Revenue Growth | 0.50 | ★ 26.34 |
| 52 Week Low | $1.67 | $23.23 |
| 52 Week High | $5.57 | $49.49 |
Technical Indicators
Market Signals| Indicator | TGB | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 57.42 | 69.04 |
| Support Level | $5.03 | $47.86 |
| Resistance Level | $5.57 | $49.49 |
| Average True Range (ATR) | 0.23 | 1.33 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 29.46 | 79.57 |
Price Performance
Historical ComparisonAbout TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.